24.91
+0.59
(2.43%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 23.37 - 25.62 |
| 52 week | 11.02 - 50.51 |
| Open | 24.49 |
| Vol / Avg. | 2.58M/1.53M |
| Mkt cap | 1.19B |
| P/E | - |
| Div/yield | - |
| EPS | -1.74 |
| Shares | 47.83M |
| Beta | 0.56 |
| Inst. own | 70% |
Events
Aug 5, 2013
Q2 2013 Infinity Pharmaceuticals, Inc. Earnings Release
Jun 11, 2013
Infinity Pharmaceuticals, Inc. Annual Shareholder Meeting
- 8:00AM EDT -
Jun 3, 2013
Infinity Pharmaceuticals, Inc. Analyst Meeting
- 9:00PM EDT -
May 21, 2013
Infinity Pharmaceuticals, Inc. at UBS Global Healthcare Conference
- 12:30PM EDT -
May 7, 2013
Q1 2013 Infinity Pharmaceuticals, Inc. Earnings Conference Call -
May 7, 2013
Q1 2013 Infinity Pharmaceuticals, Inc. Earnings Release
Apr 30, 2013
Infinity Pharmaceuticals, Inc. at Needham Healthcare Conference -
Mar 18, 2013
Infinity Pharmaceuticals, Inc. at Roth Conference -
Mar 12, 2013
Infinity Pharmaceuticals, Inc. at Sanford C Bernstein Emerging Biotech Conference
Mar 12, 2013
Infinity Pharmaceuticals, Inc. at Barclays Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | -114.54% |
| Operating margin | - | -112.09% |
| EBITD margin | - | -212.89% |
| Return on average assets | -33.77% | -23.45% |
| Return on average equity | -36.56% | -33.14% |
| Employees | 154 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company�s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).
Officers and directors
| Adelene Q. Perkins | Chairman of the Board, President, Chief Executive Officer | |
| Lawrence E. Bloch M.D., J.D. | Chief Financial Officer, Executive Vice President, Chief Business Officer | |
| Julian Adams Ph.D. | President - Research & Development | |
| Vito J. Palombella Ph.D. | Chief Scientific Officer | |
| Winselow S. Tucker Jr. | Vice President - Marketing | |
| Joshua D. Hamermesh | Vice President - Business and Corporate Development | |
| Pedro Santabarbara M.D., Ph.D. | Chief Medical Officer | |
| Anthony B. Evnin Ph.D. | Lead Outside Independent Director | |
| Martin Babler | Independent Director | |
| Gwendolyn A. Fyfe M.D. | Independent Director |